CN109153709A - 神经生长因子突变体 - Google Patents
神经生长因子突变体 Download PDFInfo
- Publication number
- CN109153709A CN109153709A CN201780017019.9A CN201780017019A CN109153709A CN 109153709 A CN109153709 A CN 109153709A CN 201780017019 A CN201780017019 A CN 201780017019A CN 109153709 A CN109153709 A CN 109153709A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- nerve growth
- mutant
- factor mutant
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 91
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims abstract description 90
- 229940053128 nerve growth factor Drugs 0.000 title claims abstract description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 27
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 19
- 239000013604 expression vector Substances 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000005036 nerve Anatomy 0.000 claims description 7
- 102220246520 rs148743497 Human genes 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 102220476301 Mis18-binding protein 1_K74L_mutation Human genes 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 102200090384 rs749060708 Human genes 0.000 claims description 5
- 102220478435 Acyl-coenzyme A thioesterase 13_D65A_mutation Human genes 0.000 claims description 4
- 102220477325 Protein XRP2_F101A_mutation Human genes 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000000869 mutational effect Effects 0.000 claims description 4
- 102200074331 rs122457137 Human genes 0.000 claims description 4
- 102220470190 Aryl hydrocarbon receptor repressor_R59A_mutation Human genes 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 102220500037 eIF5-mimic protein 2_K32G_mutation Human genes 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102220068520 rs202031614 Human genes 0.000 claims description 3
- 102200027639 rs267607256 Human genes 0.000 claims description 3
- 102220005411 rs35873730 Human genes 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000012743 protein tagging Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 230000009614 wildtype growth Effects 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 40
- 230000036407 pain Effects 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000035772 mutation Effects 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 208000000114 Pain Threshold Diseases 0.000 description 9
- 230000037040 pain threshold Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012475 sodium chloride buffer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 101150064037 NGF gene Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000046917 human NGF Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- -1 salinity Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
神经生长因子突变体,为序列表SEQ ID No:3至SEQ ID No:21中任意一条所示的氨基酸序列。其优点在于:神经生长因子突变可以减轻疼痛副作用,属于生物制药领域。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210214942.4A CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN202210214938.8A CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN202210214934.XA CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610159303 | 2016-03-18 | ||
CN2016101593037 | 2016-03-18 | ||
PCT/CN2017/077038 WO2017157326A1 (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210214934.XA Division CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN202210214942.4A Division CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN202210214938.8A Division CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109153709A true CN109153709A (zh) | 2019-01-04 |
CN109153709B CN109153709B (zh) | 2022-05-27 |
Family
ID=59850520
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210214934.XA Active CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN201780017019.9A Active CN109153709B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN202210214938.8A Active CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN201780017018.4A Active CN109071678B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子融合蛋白、制备方法及其用途 |
CN202210214942.4A Withdrawn CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210214934.XA Active CN114671940B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210214938.8A Active CN114671941B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
CN201780017018.4A Active CN109071678B (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子融合蛋白、制备方法及其用途 |
CN202210214942.4A Withdrawn CN114671942A (zh) | 2016-03-18 | 2017-03-17 | 神经生长因子突变体 |
Country Status (7)
Country | Link |
---|---|
US (4) | US11883464B2 (zh) |
EP (3) | EP3431507B1 (zh) |
CN (5) | CN114671940B (zh) |
DK (1) | DK3431507T3 (zh) |
ES (1) | ES2966133T3 (zh) |
HU (1) | HUE064504T2 (zh) |
WO (2) | WO2017157326A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE064504T2 (hu) | 2016-03-18 | 2024-03-28 | Staidson Beijing Biopharmaceuticals Co Ltd | Idegi növekedési faktort tartalmazó fúziós fehérje, valamint elõállítási eljárása és alkalmazása |
CN113845583B (zh) * | 2020-06-28 | 2023-08-11 | 江苏中新医药有限公司 | 一种修饰的重组人神经生长因子及其制备方法 |
WO2022105847A1 (en) | 2020-11-19 | 2022-05-27 | Staidson (Beijing) Biopharmaceuticals Co. , Ltd. | Long-acting nerve growth factor polypeptides and uses thereof |
CN115894705A (zh) * | 2021-09-30 | 2023-04-04 | 三生国健药业(上海)股份有限公司 | 一种β-NGF融合蛋白、其制备方法及用途 |
WO2023088351A1 (zh) * | 2021-11-19 | 2023-05-25 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子在制备用于治疗或改善生殖系统疾病的药物中的用途 |
EP4342485A1 (en) * | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
CN115813951B (zh) * | 2022-11-10 | 2023-07-21 | 北京昱龙盛世生物科技有限公司 | 转基因干细胞及其用于治疗失眠症或睡眠障碍的用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1079992A (zh) * | 1992-03-06 | 1993-12-29 | 哈肯·本特·佩尔松 | 具有经改变的受体结合特性的神经营养因子 |
CN1698883A (zh) * | 2004-05-21 | 2005-11-23 | 舒泰神(北京)药业有限公司 | 神经生长因子在制备有效减轻体重的药物中的应用 |
WO2008006893A1 (en) * | 2006-07-13 | 2008-01-17 | Lay Line Genomics S.P.A. | Muteins of hngf, therapeutic uses and pharmaceutical compositions |
US7452863B1 (en) * | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
WO2009080823A2 (en) * | 2007-12-20 | 2009-07-02 | Cytos Biotechnology Ag | Nerve growth factor conjugates and uses thereof |
US7935671B2 (en) * | 1994-06-03 | 2011-05-03 | Genentech, Inc. | Pantropic neurotrophic factors |
CN103159843A (zh) * | 2011-12-19 | 2013-06-19 | 中国科学院生物物理研究所 | 具有低免疫副作用的神经生长因子突变体的制备方法及其药物应用价值 |
CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1689865A2 (en) * | 2003-10-23 | 2006-08-16 | Monika Holmberg | A novel mutated nerve growth factor beta gene, proteins encoded thereby, and products and methods related thereto |
ATE409741T1 (de) * | 2004-01-19 | 2008-10-15 | Nsgene As | Nervenwachstumsfaktor sezernierende menschliche therapeutische zellen |
CN101260398B (zh) * | 2007-03-07 | 2013-06-05 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子基因定位改造动物及其制备方法和应用 |
CA2778864C (en) | 2009-11-19 | 2017-06-27 | Merck Serono S.A. | Humanized antibodies against human il-22ra |
WO2012075340A2 (en) * | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
CN102898514B (zh) * | 2011-07-28 | 2015-04-29 | 中国人民解放军军事医学科学院生物工程研究所 | 重组人神经生长因子缺失突变体及其制备方法和用途 |
CN103376248B (zh) | 2012-04-26 | 2016-06-01 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子活性定量测定方法 |
HUE064504T2 (hu) | 2016-03-18 | 2024-03-28 | Staidson Beijing Biopharmaceuticals Co Ltd | Idegi növekedési faktort tartalmazó fúziós fehérje, valamint elõállítási eljárása és alkalmazása |
-
2017
- 2017-03-17 HU HUE17765867A patent/HUE064504T2/hu unknown
- 2017-03-17 WO PCT/CN2017/077038 patent/WO2017157326A1/zh active Application Filing
- 2017-03-17 CN CN202210214934.XA patent/CN114671940B/zh active Active
- 2017-03-17 US US16/085,984 patent/US11883464B2/en active Active
- 2017-03-17 CN CN201780017019.9A patent/CN109153709B/zh active Active
- 2017-03-17 CN CN202210214938.8A patent/CN114671941B/zh active Active
- 2017-03-17 US US16/085,977 patent/US11213568B2/en active Active
- 2017-03-17 EP EP17765867.1A patent/EP3431507B1/en active Active
- 2017-03-17 DK DK17765867.1T patent/DK3431507T3/da active
- 2017-03-17 CN CN201780017018.4A patent/CN109071678B/zh active Active
- 2017-03-17 WO PCT/CN2017/077025 patent/WO2017157325A1/zh active Application Filing
- 2017-03-17 EP EP23203486.8A patent/EP4292649A3/en active Pending
- 2017-03-17 ES ES17765867T patent/ES2966133T3/es active Active
- 2017-03-17 EP EP17765868.9A patent/EP3431494B1/en active Active
- 2017-03-17 CN CN202210214942.4A patent/CN114671942A/zh not_active Withdrawn
-
2021
- 2021-11-19 US US17/455,870 patent/US20220088136A1/en not_active Abandoned
-
2023
- 2023-02-07 US US18/165,801 patent/US20230241169A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1079992A (zh) * | 1992-03-06 | 1993-12-29 | 哈肯·本特·佩尔松 | 具有经改变的受体结合特性的神经营养因子 |
US7935671B2 (en) * | 1994-06-03 | 2011-05-03 | Genentech, Inc. | Pantropic neurotrophic factors |
US7452863B1 (en) * | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
US8101571B2 (en) * | 1997-04-29 | 2012-01-24 | Genentech, Inc. | Treatment methods using NGF variants |
CN1698883A (zh) * | 2004-05-21 | 2005-11-23 | 舒泰神(北京)药业有限公司 | 神经生长因子在制备有效减轻体重的药物中的应用 |
WO2008006893A1 (en) * | 2006-07-13 | 2008-01-17 | Lay Line Genomics S.P.A. | Muteins of hngf, therapeutic uses and pharmaceutical compositions |
WO2009080823A2 (en) * | 2007-12-20 | 2009-07-02 | Cytos Biotechnology Ag | Nerve growth factor conjugates and uses thereof |
CN103159843A (zh) * | 2011-12-19 | 2013-06-19 | 中国科学院生物物理研究所 | 具有低免疫副作用的神经生长因子突变体的制备方法及其药物应用价值 |
CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
Non-Patent Citations (1)
Title |
---|
C.WIESMANN AND A. M. DE VOS: "Nerve growth factor: structure and function", 《CELL. MOL. LIFE SCI.》 * |
Also Published As
Publication number | Publication date |
---|---|
HUE064504T2 (hu) | 2024-03-28 |
CN109071678A (zh) | 2018-12-21 |
CN109153709B (zh) | 2022-05-27 |
US20200331977A1 (en) | 2020-10-22 |
US11883464B2 (en) | 2024-01-30 |
ES2966133T3 (es) | 2024-04-18 |
WO2017157325A1 (zh) | 2017-09-21 |
CN114671940A (zh) | 2022-06-28 |
DK3431507T3 (da) | 2024-01-02 |
CN114671940B (zh) | 2023-09-26 |
EP3431507B1 (en) | 2023-11-22 |
EP4292649A3 (en) | 2024-02-21 |
US20190105373A1 (en) | 2019-04-11 |
US20220088136A1 (en) | 2022-03-24 |
CN114671941A (zh) | 2022-06-28 |
WO2017157326A1 (zh) | 2017-09-21 |
EP3431507A4 (en) | 2019-08-14 |
CN114671941B (zh) | 2023-09-26 |
EP3431507A1 (en) | 2019-01-23 |
EP4292649A2 (en) | 2023-12-20 |
CN109071678B (zh) | 2022-05-20 |
EP3431494B1 (en) | 2024-05-01 |
US20230241169A1 (en) | 2023-08-03 |
CN114671942A (zh) | 2022-06-28 |
EP3431494A4 (en) | 2020-01-01 |
US11213568B2 (en) | 2022-01-04 |
EP3431494A1 (en) | 2019-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109153709A (zh) | 神经生长因子突变体 | |
CN110461368A (zh) | 具有变异衣壳的腺相关病毒病毒体及其使用方法 | |
CN107286233B (zh) | 低痛神经生长因子突变体 | |
JP2021038240A (ja) | 治療用化合物の眼への送達を増強する方法 | |
CN105273087A (zh) | NGF-Fc融合蛋白及其制备方法 | |
CN101134105B (zh) | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 | |
CN104830822A (zh) | 一种重组人血管舒缓素 | |
CN100457778C (zh) | 睫状神经营养因子(cntf)突变体及其生产方法和其用途 | |
US7144983B1 (en) | Pantropic neurotrophic factors | |
CN102241776B (zh) | Rankl-tnf样区融合蛋白及其制备方法和应用 | |
CN108948163A (zh) | 澳洲坚果植物防御素及其应用 | |
US20220088139A1 (en) | Nerve growth factor mutant | |
CN101897953A (zh) | 无创性高穿透性表皮生长因子及其应用 | |
CN108218978A (zh) | 一种重组白细胞介素18及其制备方法与应用 | |
CN101302529A (zh) | 共表达gdnf和bdnf的转基因神经干细胞 | |
CN106943588A (zh) | 热休克蛋白gp96在治疗银屑病中的应用 | |
CN1321690A (zh) | 一种新型双功能水蛭素及其制备方法和应用 | |
CN109689079A (zh) | 牛成纤维细胞生长因子21和乳畜中的酮病 | |
CN106983855A (zh) | 热休克蛋白gp96在治疗重症肌无力症中的应用 | |
CN115710307A (zh) | 蝎毒素及其突变体在抗癫痫中的应用 | |
CN108314721B (zh) | 人Wnt5a-NL核酸重组体及其制备方法与应用 | |
CN115974998A (zh) | 一种TNF-α拮抗肽及其应用 | |
CN117286155A (zh) | 圆环病毒3型环状rna分子、疫苗的制备及应用 | |
EA043412B1 (ru) | Соматотропин пролонгированного действия, полинуклеотид, рекомбинантная клетка, препарат | |
CN101897959A (zh) | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |